Ed Arce
Stock Analyst at HC Wainwright & Co.
(3.80)
# 767
Out of 4,761 analysts
460
Total ratings
47.06%
Success rate
9.9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ed Arce
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RARE Ultragenyx Pharmaceutical | Reiterates: Buy | $95 | $44.48 | +113.58% | 6 | Feb 18, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Reiterates: Buy | $63 | $16.92 | +272.34% | 29 | Feb 18, 2025 | |
| PLRX Pliant Therapeutics | Reiterates: Neutral | n/a | $3.01 | - | 22 | Feb 14, 2025 | |
| ENTA Enanta Pharmaceuticals | Reiterates: Buy | $18 | $8.38 | +114.80% | 11 | Feb 11, 2025 | |
| GNFT Genfit | Reiterates: Buy | $13 | $3.92 | +231.63% | 18 | Feb 7, 2025 | |
| IVA Inventiva | Reiterates: Buy | $13 | $2.74 | +374.45% | 14 | Jan 30, 2025 | |
| UNCY Unicycive Therapeutics | Reiterates: Buy | $4 | $0.61 | +555.85% | 25 | Jan 29, 2025 | |
| AKRO Akero Therapeutics | Maintains: Buy | $50 → $72 | $50.58 | +42.35% | 24 | Jan 27, 2025 | |
| AKBA Akebia Therapeutics | Reiterates: Buy | $7.5 | $1.91 | +292.67% | 34 | Jan 23, 2025 | |
| ETNB 89bio | Reiterates: Buy | $29 | $10.96 | +164.60% | 21 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $3.44 | +45.35% | 18 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $6 | $0.61 | +880.39% | 5 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5.5 | $5.72 | -3.85% | 8 | Jan 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $22 | $23.58 | -6.70% | 20 | Jan 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $48 | $19.00 | +152.63% | 2 | Jan 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $390 → $400 | $351.03 | +13.95% | 16 | Jan 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $0.68 | +1,659.01% | 16 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $1.64 | +631.71% | 1 | Dec 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.47 | - | 16 | Dec 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $12.75 | - | 7 | Dec 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $7.5 | $4.13 | +81.60% | 11 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $32 | $4.03 | +695.03% | 9 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $0.81 | - | 12 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $66 | $53.16 | +24.15% | 29 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $24 | $22.38 | +7.24% | 21 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $75 | $20.85 | +259.71% | 4 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $1.49 | +235.57% | 13 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $13 | $7.83 | +66.03% | 16 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 → $240 | $1.22 | +19,572.13% | 4 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $1.41 | - | 8 | Mar 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $25 | $29.61 | -15.57% | 8 | Dec 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.55 | - | 4 | May 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $23.06 | - | 2 | Nov 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13,500 → $14,625 | $1.40 | +1,044,542.86% | 2 | May 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $7 | $31.63 | -77.87% | 1 | Nov 10, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $29.75 | -29.41% | 1 | Sep 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.14 | - | 2 | Feb 15, 2017 |
Ultragenyx Pharmaceutical
Feb 18, 2025
Reiterates: Buy
Price Target: $95
Current: $44.48
Upside: +113.58%
Arcturus Therapeutics Holdings
Feb 18, 2025
Reiterates: Buy
Price Target: $63
Current: $16.92
Upside: +272.34%
Pliant Therapeutics
Feb 14, 2025
Reiterates: Neutral
Price Target: n/a
Current: $3.01
Upside: -
Enanta Pharmaceuticals
Feb 11, 2025
Reiterates: Buy
Price Target: $18
Current: $8.38
Upside: +114.80%
Genfit
Feb 7, 2025
Reiterates: Buy
Price Target: $13
Current: $3.92
Upside: +231.63%
Inventiva
Jan 30, 2025
Reiterates: Buy
Price Target: $13
Current: $2.74
Upside: +374.45%
Unicycive Therapeutics
Jan 29, 2025
Reiterates: Buy
Price Target: $4
Current: $0.61
Upside: +555.85%
Akero Therapeutics
Jan 27, 2025
Maintains: Buy
Price Target: $50 → $72
Current: $50.58
Upside: +42.35%
Akebia Therapeutics
Jan 23, 2025
Reiterates: Buy
Price Target: $7.5
Current: $1.91
Upside: +292.67%
89bio
Jan 21, 2025
Reiterates: Buy
Price Target: $29
Current: $10.96
Upside: +164.60%
Jan 21, 2025
Reiterates: Buy
Price Target: $5
Current: $3.44
Upside: +45.35%
Jan 21, 2025
Reiterates: Buy
Price Target: $6
Current: $0.61
Upside: +880.39%
Jan 16, 2025
Reiterates: Neutral
Price Target: $5.5
Current: $5.72
Upside: -3.85%
Jan 15, 2025
Maintains: Buy
Price Target: $18 → $22
Current: $23.58
Upside: -6.70%
Jan 14, 2025
Reiterates: Buy
Price Target: $48
Current: $19.00
Upside: +152.63%
Jan 14, 2025
Maintains: Buy
Price Target: $390 → $400
Current: $351.03
Upside: +13.95%
Jan 13, 2025
Reiterates: Buy
Price Target: $12
Current: $0.68
Upside: +1,659.01%
Dec 30, 2024
Initiates: Buy
Price Target: $12
Current: $1.64
Upside: +631.71%
Dec 27, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.47
Upside: -
Dec 27, 2024
Reiterates: Neutral
Price Target: n/a
Current: $12.75
Upside: -
Dec 4, 2024
Reiterates: Neutral
Price Target: $7.5
Current: $4.13
Upside: +81.60%
Nov 15, 2024
Reiterates: Buy
Price Target: $32
Current: $4.03
Upside: +695.03%
Nov 14, 2024
Reiterates: Neutral
Price Target: n/a
Current: $0.81
Upside: -
Nov 13, 2024
Reiterates: Buy
Price Target: $66
Current: $53.16
Upside: +24.15%
Nov 11, 2024
Reiterates: Buy
Price Target: $24
Current: $22.38
Upside: +7.24%
Nov 7, 2024
Reiterates: Buy
Price Target: $75
Current: $20.85
Upside: +259.71%
Sep 10, 2024
Reiterates: Buy
Price Target: $5
Current: $1.49
Upside: +235.57%
Sep 6, 2024
Reiterates: Buy
Price Target: $13
Current: $7.83
Upside: +66.03%
Mar 26, 2024
Reiterates: Buy
Price Target: $12 → $240
Current: $1.22
Upside: +19,572.13%
Mar 20, 2024
Upgrades: Neutral
Price Target: n/a
Current: $1.41
Upside: -
Dec 27, 2023
Reiterates: Buy
Price Target: $25
Current: $29.61
Upside: -15.57%
May 3, 2022
Downgrades: Neutral
Price Target: n/a
Current: $2.55
Upside: -
Nov 18, 2020
Downgrades: Neutral
Price Target: n/a
Current: $23.06
Upside: -
May 12, 2020
Maintains: Buy
Price Target: $13,500 → $14,625
Current: $1.40
Upside: +1,044,542.86%
Nov 10, 2017
Assumes: Buy
Price Target: $7
Current: $31.63
Upside: -77.87%
Sep 11, 2017
Initiates: Buy
Price Target: $21
Current: $29.75
Upside: -29.41%
Feb 15, 2017
Downgrades: Neutral
Price Target: n/a
Current: $3.14
Upside: -